22:29 , Sep 21, 2018 |  BC Extra  |  Company News

Management tracks: Ex-MiMedx execs to lose compensation

MiMedx Group Inc. (NASDAQ:MDXG) said it will treat four resignations announced this summer, including that of former Chairman and CEO Parker Petit, as "for cause" terminations. The regenerative medicine and biologics company said the decision,...
20:38 , Sep 21, 2018 |  BioCentury  |  Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
22:58 , Sep 14, 2018 |  BioCentury  |  Regulation

Closing NICE’s Orphan gap

As the list of Orphan drugs rejected by NICE grows, industry and patient groups are pressuring the agency to make broader use of tools that currently apply only to selected ultra-Orphan therapies. These tools allow...
23:56 , Sep 13, 2018 |  BC Extra  |  Company News

ICER panel: hATTR treatments have low value

The Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council (CEPAC) voted unanimously in separate tallies that the long-term value for money was low for hATTR treatments from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
23:41 , Sep 7, 2018 |  BC Extra  |  Company News

CF Trust: U.K. health secretary backs NHS in Vertex stalemate

Secretary of State for Health and Social Care Matt Hancock told the Cystic Fibrosis Trust that he is not willing to let Orkambi ivacaftor/lumacaftor set a precedent that will “expose the NHS to accepting the...
19:06 , Sep 7, 2018 |  BC Extra  |  Financial News

RNAi company Dicerna raises $100M follow-on

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.79 (14%) to $14.81 on Friday after raising $100 million via the sale of 7.7 million shares at $13.02 in a follow-on underwritten by Citigroup, Leerink, Stifel, H.C. Wainwright and...
00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
18:50 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Onpattro approved in Europe as ICER says not cost-effective

The European Commission approved Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) on Aug. 30, a day after the Institute for Clinical and Economic Review concluded the drug is not...
22:41 , Aug 30, 2018 |  BC Extra  |  Company News

Onpattro approved in Europe as ICER says not cost-effective

The European Commission approved Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for hereditary transthyretin (TTR)-mediated amyloidosis (hATTR), a day after the Institute for Clinical and Economic Review concluded the drug is not cost-effective based on...